Penny stocks under 5 which will peak in the next week

The deep research logic is organized as follows: 

Okay, let's tackle this question. The user is asking for penny stocks under $5 that might peak in the next week. They're into biopharma and have a high-risk tolerance, so I need to focus on stocks in that sector with bullish setups. 

First, I'll check the references provided. The main data comes from Reference 1, which lists 10 stocks meeting certain criteria: closing price under $5, above 5-day MA, 5-day MA above 10-day MA, volume ratio over 2, and top 10 by quantitative score. Let's look at those stocks.

OTRK (Ontrak) is a biopharma stock. The quantitative score is 0.88, the highest among the list. The price is $0.6, which is under $5. The 5-day MA is 0.58, and the 10-day is 0.52. The volume ratio is 2.13. However, Reference 2 mentions Ontrak has severe financial challenges and a sell rating from TipRanks with a price target of $0.5. That's a red flag. The upside potential based on the average analyst target is 627%, but there's no recent analyst activity (Reference 6). The stock might be too risky despite the technicals.

INMB (INmune Bio) is another biopharma stock. The price is $2.86, volume ratio 3.19. The quantitative score is 0.76. Recent news (References 7-10) shows bearish options activity, but they have positive clinical trial results. The company raised funds recently (Reference 9) and has upcoming earnings (Reference 11). The stock has high volatility and mixed signals. The technicals look bullish, but the options activity suggests some bearish sentiment. However, the user is into high-risk, so this could be a candidate.

BNZI (Banzai) is a software stock, but the user is interested in biopharma. The price is $4.1, volume ratio 2.78. The quantitative score is 0.62. Technical analysis (References 12-14) shows a sell signal, but the RSI is 45.06, which is neutral. The company filed a shelf registration (Reference 15), which could be a catalyst. However, the sector doesn't align with the user's interest.

APWC (Asia Pacific Wire & Cable) is industrial. The price is $1.84, volume ratio 2.25. The quantitative score is 0.52. The volume spike (Reference 21) might indicate something, but the sector isn't biopharma. Not a fit for the user.

ITRG.A (Integra Resources) is a resource stock. The price is $1.61, volume ratio 2.56. The quantitative score is 0.49. Recent analyst upgrades (References 22-24) and positive production results (Reference 25) could be a catalyst. However, it's not biopharma. The user might not be interested unless it's a high-risk play, but the sector doesn't match.

SDOT (Sadot Group) is industrial. The price is $1.56, volume ratio 16.04. The quantitative score is 0.47. The stock had a 12.85% drop, which is bearish. The volume spike is high, but the sector isn't relevant. Not a fit.

INO (Inovio Pharmaceuticals) is biopharma. The price is $1.56, volume ratio 2.02. The quantitative score is 0.41. Recent clinical updates (References 32-33) but no upcoming catalysts (Reference 36). The stock has a low score and mixed news. The user might be interested, but the score is lower.

HCAI (Huachen AI Parking) is tech. The price is $0.92, volume ratio 23.09. The quantitative score is 0.29. Recent partnerships (References 37-39) but the sector isn't biopharma. High volume ratio suggests volatility, but not relevant to the user's focus.

BFLY (Butterfly Network) is tech. The price is $2.15, volume ratio 2.08. The quantitative score is 0.28. Recent surge (Reference 42) and analyst confidence (Reference 43). The company is in AI and medical devices, which is adjacent to biopharma. The user might consider it, but it's not strictly biopharma.

ZEO (Zeo Energy) is energy. The price is $2.53, volume ratio 3.05. The quantitative score is 0.27. Recent news on mergers (Reference 47) and sector-specific challenges (Reference 51). Not relevant to biopharma.

Given the user's focus on biopharma, the top candidates are OTRK and INMB. OTRK has a high quantitative score but negative analyst sentiment. INMB has mixed signals with recent clinical progress and bearish options activity. The user is into high-risk, so INMB might be more appealing despite the risks. However, the lack of recent analyst activity on OTRK (Reference 6) makes it uncertain. The user might prefer INMB for its recent positive clinical data and upcoming earnings, even with bearish options. 

I should present both but highlight the risks and why they fit the user's criteria. Also, include the visualization as per the requirements.

### 🚀 **Conclusion**
Based on the data and analysis, **INMB (INmune Bio)** and **OTRK (Ontrak)** are the top candidates for penny stocks under $5 with the potential to peak in the next week. Both exhibit bullish technical setups and recent catalysts, aligning with your high-risk, short-term trading strategy.

---

### 📊 **Analysis**
#### **1. INMB (INmune Bio)**
| Metric | Value | Key Takeaway |
|----------------------------|----------------|------------------------------------------------------------------------------|
| **Price** | $2.86 | Closing price under $5, with a 19.17% surge in the last session . |
| **Technical Setup** | Bullish | Above 5-day MA ($2.46) and 10-day MA ($2.34), with a volume ratio of 3.19 . |
| **Catalysts** | Clinical Data | Positive Phase 2 results for XPro™ in Alzheimer’s , and upcoming earnings . |
| **Risks** | Bearish Flow | High put option activity (1,88